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Background. Increased monocyte activation and intestinal damage have been shown to be predictive for the increased morbid-
ity and mortality observed in treated people living with human immunodeficiency virus (PLHIV).
Methods. A cross-sectional analysis of cellular and soluble markers of monocyte activation, coagulation, intestinal damage, and 
inflammation in plasma and cerebrospinal fluid (CSF) of PLHIV with suppressed plasma viremia on combination antiretroviral 
therapy and age and demographically comparable HIV-negative individuals participating in the Comorbidity in Relation to AIDS 
(COBRA) cohort and, where appropriate, age-matched blood bank donors (BBD).
Results. People living with HIV, HIV-negative individuals, and BBD had comparable percentages of classical, intermediate, 
and nonclassical monocytes. Expression of CD163, CD32, CD64, HLA-DR, CD38, CD40, CD86, CD91, CD11c, and CX3CR1 on 
monocytes did not differ between PLHIV and HIV-negative individuals, but it differed significantly from BBD. Principal component 
analysis revealed that 57.5% of PLHIV and 62.5% of HIV-negative individuals had a high monocyte activation profile compared 
with 2.9% of BBD. Cellular monocyte activation in the COBRA cohort was strongly associated with soluble markers of monocyte 
activation and inflammation in the CSF.
Conclusions. People living with HIV and HIV-negative COBRA participants had high levels of cellular monocyte activation 
compared with age-matched BBD. High monocyte activation was predictive for inflammation in the CSF.
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Successfully treated people living with human immunodefi-
ciency virus (PLHIV) are reported to have higher rates of age- 
associated noncommunicable diseases (AANCCs) and a shorter 
average life expectancy compared with uninfected persons of 
the same age [1–3]. In addition to a higher prevalence of tra-
ditional risk factors for these AANCCs in PLHIV, combination 
antiretroviral therapy (cART) toxicity, chronic immune activa-
tion, and immune dysfunction have all been suggested to con-
tribute to their development [4]. Several mechanisms have been 
proposed to explain the reported heightened inflammatory state 
observed in PLHIV, including (residual) HIV replication, HIV-
mediated increased gut permeability and gut microbial trans-
location, coinfections with other viruses (ie, cytomegalovirus 
[CMV], hepatitis B virus [HBV], and hepatitis C virus [HCV]), 
and loss of immune regulatory responses [4–6]. Although 
cART reduces chronic immune activation, there remains evi-
dence of continued high levels of T-cell activation [7, 8], cel-
lular monocyte activation [9, 10], soluble monocyte activation 
markers [9, 11, 12], and inflammation [12–14] in PLHIV with 
suppressed plasma viremia on treatment. Furthermore, PLHIV 
were also shown to have persistently elevated concentrations 
of monocyte activation and inflammation in the cerebrospinal 
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fluid (CSF) despite cART [15–17]. It is interesting to note that 
plasma markers of monocyte activation, inflammation, and 
intestinal damage (I-FABP), but not T-cell activation, have been 
found to be strong predictors of morbidity and mortality in 
treated PLHIV [18–20], suggesting that monocyte activation 
may be relevant to the pathogenesis underlying the increased 
morbidity and mortality that is seen in treated PLHIV. In this 
study, we analyzed cellular and soluble markers of monocyte 
activation, coagulation, intestinal damage, and inflammation in 
plasma and CSF of PLHIV on suppressive cART participating 
in the European Commission-funded Comorbidity in Relation 
to AIDS (COBRA) cohort study. These results were compared 
with those seen in a group of demographically comparable HIV-
negative COBRA participants and, where appropriate, with age-
matched blood bank donors (BBD). Furthermore, we analyzed 
the relation between markers of cellular monocyte activation 
and soluble markers of monocyte activation, intestinal damage, 
and inflammation in plasma and CSF of the PLHIV and HIV-
negative COBRA participants.
MATERIALS AND METHODS
Subjects
The COBRA study included 134 PLHIV on cART and 79 
demographically and lifestyle comparable HIV-negative con-
trol subjects from sites in London and Amsterdam in a detailed, 
prospective evaluation of the impact of HIV infection on the 
prevalence, incidence, and age at onset of AANCC. Exclusion 
criteria were as follows: age under 45 years (50 years for London 
participants); self-reported current intravenous drug use (in 
the past 6  months); daily use of recreational drugs (with the 
exception of cannabis); excess alcohol intake (>48 units per 
week); (history of) confounding neurological diseases; severe 
head injury (loss of consciousness for >30 minutes); infections 
or tumors involving the central nervous system ([CNS] includ-
ing acquired immune deficiency syndrome-defining illnesses); 
current major depression (Patient Health Questionnaire-9 
questionnaire score ≥15); self-reported current intravenous 
drug use in the past 6 months; daily use of recreational drugs 
(with the exception of cannabis); excess alcohol consumption 
(>48 units per week); severe psychiatric disorders; insufficient 
command of the Dutch/English language; and a contraindica-
tion to magnetic resonance imaging or lumbar puncture [50, 
51]. All PLHIV were required to be on cART and to have had 
undetectable plasma HIV ribonucleic acid ([RNA] <50 copies/
mL) for ≥12 months before enrollment. For the present immu-
nological substudy, 40 PLHIV and 40 HIV-negative control 
participants were randomly selected with equal numbers in 
each of the following age groups: 45–50, 51–55, 56–60, 61–65, 
66–70, and 70+, except for the oldest age category in which only 
a few individuals were available. Materials from 35 BBD were 
obtained from the Dutch national blood bank in Amsterdam, 
the Netherlands (www.sanquin.nl). Blood bank donors (median 
age, 58 years; interquartile range [IQR], 52–65) were matched 
for age with the PLHIV (median age, 58.5 years; IQR, 53–63) 
and HIV-negative COBRA participants (median age, 59 years; 
IQR, 53–64) and were selected in such a way that the differ-
ent COBRA age categories (other than the 70+ category) were 
equally represented. Blood bank donors from the Netherlands 
were actively screened for HIV, HBV, HCV, syphilis, and human 
T-lymphotropic virus (HTLV) infection. Potential BBD were 
excluded from blood donation if they were determined to be 
at high risk of bloodborne infections (based on a questionnaire 
regarding general and sexual health, medication use, sexual risk 
behavior, and travel (https://www.sanquin.nl/en/give-blood/).
Ethics Statement
This study was conducted in accordance with the ethical princi-
ples set out in the declaration of Helsinki and was approved by 
the institutional review board of the Academic Medical Center, 
the UK Research Ethics Committee (Stanmore, England, ref-
erence number 13/LO/0584), and the Ethics Advisory Body of 
the Sanquin Blood Supply Foundation in Amsterdam. Written 
informed consent was obtained from all participants.
Monocyte and T-Cell Phenotyping and Flow Cytometry
Cryopreserved peripheral blood mononuclear cells (PBMCs) 
from COBRA participants and BBD were used for immune 
phenotyping. The PBMCs were thawed and subsequently 
stained with monoclonal antibodies (mAbs) for 30 minutes at 
4°C in the dark, to determine expression of different surface 
molecules. The following directly conjugated mAbs were used 
for cell surface marker staining: CD14 PE-Cy7, CD16 eFluor 
450, CD32 PerCP-eFluor 710, and CD11c APC (eBioscience, 
San Diego, CA); CD163 AlexaFluor 488 and CD86 PerCP 
(R&D Systems, Minneapolis, MN); CX3CR1 PerCP-Cy5.5 
(BioLegend, San Diego, CA); HLA-DR V500, CD3 V500, CD4 
PE-Cy7, HLA-DR fluorescein isothiocyanate (FITC), and CD38 
PE (BD Biosiences, San Jose, CA); CD38 PE and CD91 PE (BD); 
and CD40 APC-H7, CD64 APC-H7, and CD8 Pacific Blue (BD 
Pharmingen, San Diego, CA). Fluorescence was measured with 
the FACS Canto II (BD Biosciences). The proportion of cells 
and the mean fluorescence intensity (MFI) of the markers was 
determined using FlowJo 7.6 (TreeStar, Ashland, OR).
Soluble Markers in Plasma and Cerebrospinal Fluid
D-dimer and high-sensitivity C-reactive protein (CRP) con-
centrations were determined in fresh plasma samples using 
immunoturbidimetry (Sysmex CA-7000 [Siemens, Munich, 
Germany] and Cobas c702 [Roche Diagnostics, Risch-Rotkreuz, 
Switzerland]). I-FABP, sCD14, and sCD163 concentrations 
were determined in plasma and/or CSF samples stored at −80°C 
using enzyme-linked immunosorbent assay (ELISA) (I-FABP, 
CD14, and CD163 DuoSet ELISAs; R&D Systems). Soluble 
(s)CD16 concentrations were determined in plasma samples 
stored at −80°C by sandwich ELISA using mouse immuno-
globulin (Ig)G1 antihuman CD16 3G8 mAb (BD Pharmingen) 
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as capture antibody, FITC-conjugated mouse IgG antihuman 
CD16 DJ130c mAb (Dako) as detection antibody, and sheep 
IgG (Fab fragment) anti-FITC conjugated with horseradish 
peroxidase (Roche) as enzyme-linked secondary antibody, as 
described elsewhere [52]. Neopterin concentrations were meas-
ured in plasma and CSF stored at −80°C by ELISA (BRAHMS 
Diagnostics/Thermo Fisher, Henningsdorf, Berlin, Germany) 
[53]. Tryptophan and kynurenine concentrations were deter-
mined in plasma and CSF stored at −80°C by high-performance 
liquid chromatography [54]. The ratios of tryptophan/kynure-
nine were calculated as indexes of tryptophan breakdown, 
respectively. Tumor necrosis factor (TNF)α, interferon-γ-in-
ducible protein 10 (IP-10)/CXCL10, macrophage inflammatory 
protein (MIP)1α/CCL3, interleukin (IL)-6, monocyte chemo-
attractant protein (MCP)1/CCL2, MIG/CXCL9, and RANTES/
CCL5 concentrations were analyzed in plasma and CSF 
stored at −80°C by human magnetic luminex screening assay 
(LXSAHM-1 and LXSAHM-6; R&D Systems).
Cytomegalovirus total antibody titers were measured by 
ELISA-VIDITEST anti-CMV-IgG and IgG avidity (VIDIA, 
Praha, Czech Republic) according to the manufacturer’s 
instruction. For quantification, a standard curve was prepared 
by serial dilution of plasma from a known CMV-seropositive 
individual.
Viral Load in Plasma and Cerebrospinal Fluid
Cerebrospinal fluid and plasma HIV RNA copy number was 
measured in stored CSF (−80°C) and fresh plasma samples 
using the Abbott RealTime M2000 assay (Abbot, Chicago, IL) 
with a lower limit of detection of 40 copies/mL.
Statistical Analysis
Differences in subject characteristics between groups were 
assessed using Student’s t test, Mann-Whitney U test, or 
Pearson χ2 test, as appropriate. Significant differences of immu-
nological markers between PLHIV, HIV-negative COBRA par-
ticipants, and BBD were evaluated using multivariable linear 
regression adjusting for age and gender because some of the 
cellular markers are influenced by age and gender [55, 56]. 
Some outcomes were log10 transformed to attain normality as 
indicated. No formal Bonferroni correction was applied to P 
values due to its conservative nature when many tests are per-
formed. Instead, principal components analysis (PCA) was per-
formed to reduce the dimension of the dataset by allowing us to 
identify 1 or more linear combinations of expression markers, 
which together explain a reasonable proportion of the variation 
observed in the PLHIV, HIV-negative COBRA participants, 
and BBD. Therefore, our primary analysis focuses on the com-
parison of these linear combinations between groups. Principal 
components analysis was performed on the normalized MFIs 
of CD163, CD32, CD64, CD38, HLA-DR, CD40, CD86, CD91, 
CD11c, and CX3CR1 on the classical, intermediate, and non-
classical monocyte subsets. Analyses were performed in IBM 
SPSS Statistics for Windows version 23 (IBM, Armonk, NY), 
RStudio version 0.99.903 (RStudio, Inc., Boston, MA), and 
GraphPad Prism 6 (GraphPad, La Jolla, CA).
RESULTS
Baseline Characteristics of Comorbidity in Relation to AIDS Participants 
and Blood Bank Donors
People living with HIV and HIV-negative controls had a 
median age of 58.5 (IQR, 53–63) and 59 (IQR, 53–63) years, 
respectively. People living with HIV had been diagnosed with 
HIV for a median of 13.9 (IQR, 9.1–18.7) years, had been on 
cART for a median of 12.2 (IQR, 7.9–16.9) years, and had spent 
a median of 8.0 (IQR, 5.3–10.9) years with undetectable plasma 
HIV RNA (Table 1). All PLHIV had undetectable HIV RNA in 
CSF. Although the percentage of males did not differ signifi-
cantly between the PLHIV and HIV-negative COBRA partic-
ipants, it was significantly lower in the group of BBD. Despite 
long-term suppression of HIV-replication by cART, PLHIV 
in COBRA exhibited incomplete CD4+ T-cell restoration and 
greater CD8+ T-cell counts compared with HIV-negative par-
ticipants, as reflected by lower CD4 counts, higher CD8 counts, 
and an inverted CD4/CD8 T-cell ratio (Table 1).
Monocyte Activation in People Living With Human Immunodeficiency 
Virus (HIV) and HIV-Negative Comorbidity in Relation to AIDS Participants 
and Blood Bank Donors
The percentages of classical (CD14+CD16−), intermediate 
(CD14+CD16+), and nonclassical (CD14+CD16++) monocytes 
did not differ significantly between PLHIV and HIV-negative 
COBRA participants. Furthermore, percentages of classical, 
intermediate, and nonclassical monocytes in BBD were com-
pared with PLHIV and HIV-negative COBRA participants 
(Figure 1a). Monocyte subsets were analyzed for their expres-
sion of activation markers (CD163, CD32, CD64, HLA-DR, 
CD38), T-cell costimulatory molecules (CD40 and CD86), and 
adhesion molecules (CD91, CD11c, and CX3CR1). The expres-
sion of activation, costimulatory, and adhesion markers did 
not differ between PLHIV and HIV-negative COBRA partic-
ipants, except for the expression of CD163 and CD32 (Figure 
1b; Supplementary Table 1). CD163 expression was higher and 
CD32 expression was lower on nonclassical monocytes of PLHIV 
compared with HIV-negative COBRA participants (Figure 1b). 
Strikingly, both PLHIV and HIV-negative COBRA participants 
compared with BBD had distinct differences in the expression 
of monocyte activation and costimulatory and adhesion mole-
cules. Compared with BBD, expression of CD163 was higher on 
classical monocytes and lower on intermediate and nonclassi-
cal monocytes of both groups of COBRA participants (Figure 
1b). Expression of CD32 was higher on classical and nonclas-
sical monocytes of COBRA participants, whereas expression 
of CD64 and CD86 was higher on both classical and interme-
diate monocytes of COBRA participants compared with BBD. 
Expression of HLA-DR, CD86, CD91, CD11c, and CX3CR1 
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was higher on all monocyte subpopulations of both PLHIV and 
HIV-negative COBRA participants compared with BBD (Figure 
1b). Expression of CD38 was not different on classical and inter-
mediate monocytes, but it was lower on nonclassical monocytes 
of PLHIV and HIV-negative COBRA participants compared 
with BBD. Expression of CD40 was lower on all monocyte sub-
populations of PLHIV and HIV-negative COBRA participants 
compared with BBD (Figure 1b).
Principal Components Analysis Identifies Distinct Monocyte Activation 
Patterns in People Living With Human Immunodeficiency Virus (HIV) and 
HIV-Negative Comorbidity in Relation to AIDS Participants
The first principal component (PC1) explained 39.3% of the 
variation in expression of monocyte activation and costimula-
tion and adhesion markers, whereas the second (PC2) explained 
15.3% of this variation. The loadings plot shows that the mark-
ers CD32, CD64, HLA-DR, CD38, CD86, CD91, and CX3CR1 
largely cluster together, whereas separate clusters of CD11c and 
CD163 together with CD40 were observed (Figure  2a). The 
PC1 is negatively correlated with CD163 and CD40 expression, 
whereas it is positively associated with CD64, HLA-DR, CD38, 
and CD11c expression. On the other hand, PC2 shows a relatively 
similar but opposite pattern of associations. When PLHIV, HIV-
negative COBRA participants, and BBD are plotted based on 
PC1 and PC2, 2 very distinct clusters are observed (Figure 2b). 
Cluster 1 consists of 34 BBD, 17 PLHIV, and 15 HIV-negative 
COBRA participants with a low score for PC1 and a high score 
for PC2 indicating a low level of monocyte activation, whereas 
cluster 2 consists mainly of PLHIV (n = 23) and HIV-negative 
COBRA participants (n = 25) with a high score for PC1 and a low 
score for PC2 indicating a high monocyte activation (Figure 2b). 
Although the frequency of individuals with high or low mono-
cyte activation did not differ significantly between PLHIV and 
HIV-negative COBRA participants, all but 1 BBD were classified 
as having low monocyte activation (Figure 2c).
When the PCA was performed using data from only the 
COBRA participants, PC1 and PC2 explained 11.1% and 4.1%, 
respectively, of the variation in expression of monocyte activa-
tion, costimulation, and adhesion markers within COBRA. In 
Table 1. Baseline Characteristics PLHIV, HIV-Negative COBRA Participants, and Blood Bank Donors
Baseline Characteristics
PLHIV n = 40 HIV Negative n = 40 PLHIV vs HIV Negative BBD n = 35 PLHIV vs BBD
HIV Negative 
vs BBD
n (%) or Median (IQR) n (%) or Median (IQR) P Valuea
n (%) or Median 
(IQR) P Valuea P Valuea
Age (years) 58.5 (53.5–63.5) 59.0 (53.0–64.5) .9 58 (52.0–65.0) .5 .5
Male sex 36 (90.0%) 37 (92.5%) .7 18 (51.4%) <.001 <.001
African descent 5 (12.5%) 1 (2.5%) .09 n.a.
MSM 32 (80.0%) 30 (75.0%) .8 n.a.
CMV 38 (95.0%) 31 (77.5%) .02 8 (22.9%) <.001 <.001
Alcohol consumption
(units/week)
7.7 (1–9) 5.6 (1–8) .3 n.a.
Recreational drug-use in past 6 months 6 (15%) 13 (33%) .1 n.a.
Smoking status .3
 Never smoked 12 (30%) 10 (25%) n.a.
 Ex-smoker 15 (37.5%) 22 (55%) n.a.
 Current smoker 13 (32.5%) 8 (20%) n.a.
HBV 21 (52.5%) 7 (17.5%) .001 n.a.
Chronic HBV 3 (7.5%) 0 (0%) .07 n.a.
HCV 6 (15%) 0 (0%) .01 0 (0%) .02 n.d.
Chronic HCV 1 (2.5%) 0 (0%) .3 n.a
CD4 counts, cells/µL 589 (470–800) 961 (759–1233) <.001 n.a.
CD8 counts, cells/µL 762 (636–1029) 488 (364–621) <.001 n.a.
CD4/CD8 ratio 0.80 (0.61–1.13) 1.95 (1.33–2.83) <.001 n.a.
CD4 nadir, cells/µL 180 (60–180)
Years since HIV diagnosis 13.9 (9.1–18.7)
Years since start cART 12.2 (7.9–16.9)
Years undetectable plasma HIV RNA  
(<200 c/mL)b
8.0 (5.3–10.9)
Undetectable CSF HIV RNA (<40 c/mL) 40 (100%)
Abbreviations: BBD, blood bank donors; cART, combination antiretroviral therapy; CMV, cytomegalovirus; CSF, cerebrospinal fluid; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human 
immunodeficiency virus; IQR, interquartile range; MSM, men who have sex with men; n.a., not available; n.d., not determined; PLHIV, persons living with HIV; RNA, ribonucleic acid. 
Significant P values are depicted in bold.aP values calculated using Student’s t test, Mann-Whitney U test, or χ2 test or Wilcoxon’s rank-sum test where applicable.
bThe threshold was set at 200 c/mL to exclude incidental viral blips from the period in which plasma viral load was detectable.
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this analysis, a similar distribution between participants with 
high and low monocyte activation based mostly on PC1 was 
observed (Supplementary Figure 1). Monocyte activation sta-
tus in COBRA participants was not associated with CMV sta-
tus (Figure 2d) and CMV IgG antibody titers, HBV, and HCV 
serostatus (data not shown).
Systemic Markers of Immune Activation, Inflammation, Intestinal 
Damage, and Coagulation in People Living With Human 
Immunodeficiency Virus (HIV) and HIV-Negative Comorbidity in Relation 
to AIDS Participants
Concentrations of systemic markers of monocyte activa-
tion (neopterin, tryptophan, kynurenine, sCD14, sCD16, and 
sCD163), inflammation (C-reactive protein, TNFα, IP-10/
Figure 1. Phenotyping of monocytes from people living with human immunodeficiency virus (PLHIV), HIV-negative Comorbidity in Relation to AIDS (COBRA) participants and 
blood bank donors (BBD). (a) Percentages of classical (CD14+CD16−), intermediate (CD14+CD16+), and nonclassical (CD14+CD16++) monocytes of the total number of monocytes. 
(b) Relative expression of markers of activation (CD163, CD32, CD64, HLA-DR, and CD38), T-cell costimulation (CD40 and CD86), and adhesion (CD91, CD11c, and CX3CR1) 
molecules on classical, intermediate, and nonclassical monocytes. Mean fluorescence intensities (MFIs) were normalized to 100% over the classical, intermediate, and 
nonclassical monocyte subpopulations of PLHIV (red), HIV-negatives COBRA participants (blue), and BBD (gray) and represented as the mean and 95% confidence interval. 
Uncorrected P values assessed by multivariable linear regression corrected for age and gender are shown.
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CXCL10, IL-6, MCP1/CCL2, MIG/CXCL9, and RANTES/
CCL5), intestinal damage (I-FABP), coagulation (D-dimer), as 
well as CD4 T-cell counts, CD8 T-cell counts, and proportions 
of activated T cells (%CD38+HLA-DR+ CD4 and CD8 T cells) 
were compared between PLHIV and HIV-negative COBRA 
participants and between individuals with high or low mono-
cyte activation as determined by PCA. The PLHIV partici-
pants had lower CD4 T-cell counts, higher CD8 T-cell counts, 
higher concentrations of activated CD4+ T cells, higher plasma 
concentrations of the intestinal damage marker I-FABP, and 
higher monocyte activation markers neopterin, kynurenine, 
and sCD163 (Figure  3a; Supplementary Table  2). When the 
COBRA participants were classified based on their monocyte 
activation status, we observed that individuals with high mono-
cyte activation had lower CD8 T-cell counts, higher systemic 
concentrations of sCD163, TNFα, IL-6, and MIG/CXCL9, but 
lower concentrations of sCD16 and IP-10/CXCL10 (Figure 3a; 
Supplementary Table  2). Monocyte activation status was not 
associated with lipid levels (total cholesterol, high-density lipo-
protein cholesterol, low-density lipoprotein cholesterol, and tri-
glycerides) in the COBRA participants (data not shown).
Cerebrospinal Fluid Markers of Immune Activation and Inflammation 
in People Living With Human Immunodeficiency Virus (HIV) and HIV-
Negative Comorbidity in Relation to AIDS Participants
In addition, we analyzed the concentrations of soluble mono-
cyte activation (neopterin, tryptophan, kynurenine, sCD14 and 
sCD163) and inflammation (TNFα, IP-10/CXCL10, MIP1α/
CCL3, IL-6, MCP1/CCL2, MIG/CXCL9, and RANTES/CCL5) 
markers in the CSF of COBRA participants. The PLHIV par-
ticipants had lower tryptophan concentrations and higher 
Figure 2. Principal component analysis of cellular markers of monocyte activation, costimulation, and adhesion data from people living with human immunodeficiency 
virus (PLHIV), HIV-negative Comorbidity in Relation to AIDS (COBRA) participants, and blood bank donors (BBD). (a) Loadings plot showing the relationship between the first 
2 principal components (PC1, PC2) and the expression of CD163, CD32, CD64, HLA-DR, CD38, CD40, CD86, CD91, CD11c, and CX3CR1 on classical (●), intermediate (▼), and 
nonclassical (◆) monocytes. Each symbol shows the contribution of an individual marker to PC1 and PC2: CD163, dark gray; CD32, red; CD64, blue; HLA-DR, gray; CD38, dark 
green; CD40, dark blue; CD86, orange; CD91, black; CD11c, taupe; CX3CR1, green. (b) PLHIV (red), HIV-negative COBRA participants (blue), and BBD (gray) plotted based on the 
first 2 extracted principal components. (c) Frequency of individuals with low (green) or high (orange) cellular monocyte activation in PLHIV, HIV-negative COBRA participants, 
and BBD. (d) Cytomegalovirus (CMV)-positive (purple) and CMV-negative (green) COBRA participants plotted based on the first 2 extracted principal components.
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IP-10/CXCL10 concentrations compared with HIV-negative par-
ticipants (Figure 3b; Supplementary Table 3). Strikingly, a strong 
association was observed in COBRA participants (both PLHIV 
and HIV-negative) between peripheral cellular monocyte activa-
tion markers and soluble monocyte activation and inflammatory 
markers in the CSF (Figure 3b; Supplementary Table 3). Individuals 
with high cellular monocyte activation had lower concentrations of 
neopterin, tryptophan, and IP-10/CXCL10, a higher kynurenine/
tryptophan ratio, and higher concentrations of sCD163, TNFα, 
MIP1α/CCL3, IL-6, MCP1/CCL2, and RANTES/CCL5 compared 
with individuals with low cellular monocyte activation.
DISCUSSION
Systemic soluble markers of intestinal damage, innate immune 
activation, and inflammation such as I-FABP, sCD14, sCD163, 
indolamine 2,3-dioxygenase-1, IL-6, D-dimer, and CRP have 
been shown to be predictive for the increased morbidity and 
mortality observed in cART-treated PLHIV [18, 19]. In this study, 
cellular and soluble markers of monocyte activation, coagula-
tion, intestinal damage, and immune activation were compared 
between PLHIV with suppressed plasma and CSF HIV-RNA 
on cART and 2 age-matched HIV-negative control groups: (1) 
selected HIV-negative individuals, recruited at sexual health clin-
ics and who are comparable regarding most lifestyle and demo-
graphic factors; and (2) BBD, who were tested negative for HIV, 
HBV, HCV, syphilis, and HTLV infection and were at low risk for 
bloodborne infection. Confirming previous observations [9, 11], 
PLHIV participating in COBRA showed evidence of incomplete 
immune recovery, a damaged gut epithelial barrier, and high levels 
of monocyte activation, as reflected by lower CD4 counts, higher 
CD8 T-cell counts, a lower CD4/CD8 ratio, higher CD4+ T-cell 
activation, higher plasma concentrations of I-FABP, neopterin, 
and sCD163 compared with well matched HIV-negative COBRA 
participants. Furthermore, PLHIV had lower CSF concentrations 
of tryptophan, higher CSF concentrations of IP-10/CXCL10, and 
a trend towards higher CSF concentrations of neopterin, which 
is in line with previous studies [15, 16, 21]. Thus, our data indi-
cate that despite virological suppression, PLHIV exhibit signs of 
ongoing immune activation in both plasma and CSF. However, 
we did not confirm higher plasma concentrations of sCD14, 
Figure 3. T-cell activation and soluble markers of coagulation, gut damage, monocyte activation, and inflammation in plasma and cerebrospinal fluid (CSF). (a) Systemic 
markers of monocyte activation (neopterin, tryptophan, kynurenine, soluble [s]CD14, sCD16, and sCD163), inflammation (C-reactive protein, TNFα, IP-10/CXCL10, IL-6, MCP1/
CCL2, MIG/CXCL9, and RANTES/CCL5), intestinal damage (I-FABP), coagulation (D-dimer), and T-cell activation (%CD38+HLA-DR+ CD4 and CD8 T cells) in people living with 
human immunodeficiency virus (PLHIV) (red) and HIV-negative Comorbidity in Relation to AIDS (COBRA) participants (blue) and in all COBRA participants individuals with high 
(orange) or low (green) cellular monocyte activation. (b) Cerebrospinal fluid concentrations of monocyte activation (neopterin, tryptophan, kynurenine, sCD14, and sCD163) 
and inflammation (TNFα, IP-10/CXCL10, MIP1α/CCL3, IL-6, MCP1/CCL2, MIG/CXCL9, and RANTES/CCL5) markers in PLHIV (red) and HIV-negative COBRA participants (blue) 
and in all COBRA participants individuals with high (orange) or low (green) cellular monocyte activation. Data were normalized by Z-score normalization and represented as 
the mean and 95% confidence interval. Uncorrected P values assessed by multivariable linear regression corrected for age and gender are shown.
8 • OFID • Booiman et al
CRP, IL-6, MCP1/CCL2, MIG/CXCL9, and IP-10/CXCL10 
[9, 12–14] or higher CSF concentrations of sCD14, sCD163, 
TNFα, IL-6, MCP1/CCL2, and MIP1α/CCL3 [17] in these 
virologically suppressed PLHIV. It should also be noted that 
in addition to a convenience sample of BBD, we also included 
a HIV-negative control group that was matched to the PLHIV 
for age and was comparable regarding most lifestyle and demo-
graphic factors; this may further explain why some previous 
observations were not confirmed. Furthermore, the PLHIV in 
our study are those who are considered to be successfully treated, 
as reflected by the relatively high CD4 counts, relatively high 
CD4/CD8 ratios, and apparent greater normalization of markers 
of chronic immune activation in their plasma and CSF, compared 
with other studies [9, 12–14, 17].
Comparison of the percentages of classical, intermedi-
ate, and nonclassical monocytes between PLHIV and both 
HIV-negative COBRA participants and BBD control groups 
revealed no differences, thereby confirming previous studies 
[22, 23]. Furthermore, no striking differences were observed in 
the expression of cellular monocyte markers between PLHIV 
and the selected HIV-negative COBRA participants. However, 
when either the PLHIV or HIV-negative COBRA participants 
were compared with the BBD, higher expression of markers 
of monocyte activation (CD163, CD32, CD64, and HLA-DR), 
costimulatory molecules (CD86), and adhesion molecules 
(CD91, CD11c, and CXCR1) were observed. This suggests that 
monocytes of both PLHIV and matched HIV-negative controls 
had a higher activation level compared with BBD. The lack of 
an appropriately matched HIV-negative control group in other 
studies may be one explanation for previously reported find-
ings of an increased expression of activation markers on mono-
cytes of virologically suppressed PLHIV compared with those 
in uninfected persons [9, 10]. Therefore, our findings reiterate 
the importance of including appropriate control groups when 
conducting immunological studies such as these.
In the Netherlands, BBD are tested negative for HBV, HCV, 
syphilis, and HTLV infection, and, in addition, are selected for 
their low risk of bloodborne infections based on a question-
naire regarding their general and sexual health, medication use, 
sexual risk behavior, and travel patterns. In contrast, the HIV-
negative COBRA participants were recruited at sexual health 
clinics; due to lifestyle-related factors, these individuals are gen-
erally at higher risk for bloodborne infections than BBD. These 
differences in lifestyle-related factors may also increase their 
risk of exposure to (commensal) bacteria and viruses (eg, her-
pes viruses, papilloma viruses, polyomavirus) that trigger the 
innate immune system and thus may increase monocyte acti-
vation, without causing disease [24]. This is supported by the 
observation that CMV prevalence was higher in HIV-negative 
COBRA participants (77.5%) and lower in BBD (22.9%) than in 
the general Dutch population, 50% of whom are CMV positive 
at 50 years of age [25].
Principal components analysis of the cellular monocyte 
markers showed that PLHIV and HIV-negative COBRA par-
ticipants could be separated further into 2 groups with either 
high or low monocyte activation [9, 26–28]. High expression 
of CD64, HLA-DR, CD38, and CD11c and low expression of 
CD163 and CD40 were associated with high cellular monocyte 
activation. The percentage of individuals with high monocyte 
activation did not differ between the PLHIV and HIV-negative 
COBRA participants; however, almost all BBD were classified 
as having low monocyte activation. Differential expression of 
the molecules assessed may well affect monocyte function and 
contribute to the immunological perturbations observed in 
these individuals [4]. High expression of Fcγ receptor 1 (CD64) 
may increase activation upon recognition of IgG and subse-
quent production of several proinflammatory cytokines such as 
TNF-α, IL-6, and granulocyte-macrophage colony-stimulating 
factor [27, 29]. High expression of CD11c, which is a receptor 
for complement factor iC3b, fibrinogen, intercellular adhesion 
molecule-1, and lipopolysaccharide and is involved in endothe-
lial adhesion, may be reflective of an increased ability to migrate 
into tissues [30]. In addition, high monocyte activation was also 
associated with lower expression of CD163 and CD40. The 
hemoglobin scavenger receptor CD163 is exclusively expressed 
by monocytes and macrophages, and high expression is asso-
ciated with the immunosuppressive M2c phenotype [31–34]. 
Extracellular Toll-like receptor activation of monocytes by bac-
teria or bacterial products results in shedding of CD163, which 
may be a mechanism to dampen acute and severe monocyte 
activation [35]. Furthermore, expression of CD40 on mono-
cytes and dendritic cells is required to prime CD4+ T cells into a 
follicular homing phenotype via binding to CD40 ligand where 
they provide B cell help for effective antibody production [36, 
37]. Low or absent CD40 expression may result in impaired 
antibody production and has been linked to immunodeficien-
cies characterized by defective Ig production [38].
High cellular monocyte activation in blood of PLHIV and 
HIV-negative COBRA participants was associated with high 
concentrations of inflammatory cytokines (TNFα, MIP1α/
CCL3, IL-6, MCP1/CCL2, MIG/CXCL9, RANTES/CCL5) and 
monocyte activation markers (sCD163, tryptophan metab-
olism) in the CSF and, to a lesser extent, in plasma. We were 
surprised to find that high cellular monocyte activation was 
also associated with lower concentrations of sCD16 and IP-10/
CXCL10 in plasma and lower concentrations of IP-10/CXCL10 
and neopterin in CSF, because these are all considered mono-
cyte activation markers [39–41]. Neopterin and IP-10/CXCL10 
are both produced in response to interferon-γ [42, 43]. The 
lower concentrations of neopterin and IP-10/CXCL10 in plasma 
and CSF from individuals with high monocyte activation might 
be a reflection of diminished monocyte function in response 
to interferon-γ. Indeed, impaired monocyte function has 
been demonstrated previously [44, 45]. However, sCD16 and 
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IP-10/CXCL10 can also be produced by other cell types (natural 
killer cells and neutrophils express CD16 and endothelial cells 
also produce IP-10/CXCL10) [42, 46], and therefore it cannot 
be excluded that sCD16 and IP/CXCL10 are reflective of other 
immunological processes, especially in individuals with low 
monocyte activation. This indicates that high cellular monocyte 
activation is predictive for a specific pattern of immune activa-
tion in the CSF, which is characterized by high concentrations 
of TNFα, MIP1α/CCL3, IL-6, MCP1/CCL2, MIG/CXCL9, 
RANTES/CCL5, sCD163, and tryptophan, but low concentra-
tions of neopterin and IP-10/CXCL10.
Coinfection with viruses such as CMV, HBV, and HCV may 
contribute to the immune activation observed during treated 
HIV-infection [4, 47, 48]. We did not observe an association 
between HBV serostatus, HCV serostatus, CMV serostatus, or 
CMV IgG titers and the level of monocyte activation in COBRA 
participants. However, CMV infection was highly prevalent in 
PLHIV and HIV-negative COBRA participants, reflecting the 
high numbers of men who have sex with men in each group 
(for example, only 2 of the 40 PLHIV were CMV negative). In 
addition, the low prevalence of chronic HBV (n = 3) and HCV 
(n = 1) infection meant that we were unable to reliably assess the 
effects of coinfection with these viruses on monocyte activation.
High monocyte activation was not associated with high 
plasma concentrations of iFABP, a marker of intestinal damage, 
which suggests that microbial translocation is most likely not 
the main driver of the observed peripheral monocyte activation 
profile. However, we cannot exclude the possibility that periph-
eral monocyte activation is a reflection of lifestyle-related recent 
exposure to pathogens (bacterial or viral).
Although the cause of the peripheral monocyte activation 
profile remains unclear, the high expression of adhesion mole-
cules suggest that these cells are more prone to leave the blood 
stream and move into tissues or cross the blood-brain barrier. 
Increased influx of peripheral monocytes into the CNS may 
account for the cytokine profile observed in the CSF and may 
subsequently also augment local immune activation. Moreover, 
cytokines such as TNFα and MCP1/CCL2 are known to reduce 
blood-brain barrier integrity, which could further enhance 
influx of peripheral monocytes into the CNS and thereby 
increase CNS immune activation [49].
A limitation of our study is its cross-sectional nature. 
Ongoing longitudinal follow-up will hopefully allow us to deter-
mine whether the increased monocyte activation is persistent 
and is related to ongoing (subclinical) or future pathologies. 
Furthermore, we cannot exclude the possibility that monocyte 
activation is a reflection of lifestyle-related exposure to other 
pathogens (unrelated to disease). Another limitation of our 
study is the small sample size, which restricts our ability to detect 
small differences between groups. The large number of statistical 
tests performed may also increase the type I error rate—we did 
not formally adjust P values to take account of multiple testing, 
but instead we used a PCA approach to identify a monocyte 
activation profile for each individual. This allowed us to reduce 
the dimension of our dataset, allowing us to focus primarily on 
differences in these profiles rather than on differences in expres-
sion of each of the markers of monocyte activation. Finally, our 
cohort mostly consists of white, northern European men—rep-
lication of our findings in other populations would be of value.
CONCLUSIONS
In conclusion, markers of cellular monocyte activation did 
not differ between treated PLHIV and highly comparable, but 
HIV-negative individuals (COBRA) but were notably increased 
in both PLHIV and HIV-negative COBRA participants com-
pared with BBD. More specifically, we were able to identify a 
subset of individuals within both the PLHIV and comparable 
HIV-negative COBRA participants with high levels of cellular 
monocyte activation, which was strongly associated with high 
proinflammatory cytokine production, and markers associated 
with an increased ability of monocytes to migrate into the tis-
sues, and a decreased ability of monocytes to prime CD4+ T 
cells into a follicular homing phenotype. This shows that, in 
addition to HIV infection, there may be other (including life-
style-related) factors, specific for individuals participating in 
the COBRA cohort, that drive cellular monocyte activation and 
inflammation and may thereby contribute to the comorbidities 
often seen in these individuals. Further studies are needed to 
determine whether high cellular monocyte activation and the 
subsequent high concentrations of proinflammatory cytokines 
relate to current or future neurocognitive or other comorbidity 
frequently observed in PLHIV [1–3]. Furthermore, we observed 
that HIV-negative COBRA participants, who were broadly com-
parable to PLHIV regarding most lifestyle and demographic 
factors, have greater immune activation compared with BBC. 
The potential clinical importance of this finding, particularly 
regarding future risk of complications associated with persis-
tent immune activation, remains to be determined.
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